Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting

NCT02064049 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT02064049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02064049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting
Lead sponsor
Kirby Institute
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2014
Completion date
November 30, 2019
Enrollment
3,692 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c